相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Envafolimab: First Approval
Anthony Markham
DRUGS (2022)
The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity
Mark F. Maurer et al.
NATURE COMMUNICATIONS (2022)
T Cell-Mediated Targeted Delivery of Anti-PD-L1 Nanobody Overcomes Poor Antibody Penetration and Improves PD-L1 Blocking at the Tumor Site
Pierre -Florent Petit et al.
CANCER IMMUNOLOGY RESEARCH (2022)
Discovery of Anti-PD-L1 Human Domain Antibodies for Cancer Immunotherapy
Hao Liu et al.
FRONTIERS IN IMMUNOLOGY (2022)
Autoimmune Polyendocrinopathy Induced by an Antibody (KN046) That Simultaneously Inhibits PD-L1 and CTLA-4: A Case Report and Literature Review
Min Li et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2022)
Development of a Non-IgG PD-1/PD-L1 Inhibitor by in Silico Mutagenesis and an In-Cell Protein-Protein Interaction Assay
Boyang Ning et al.
ACS CHEMICAL BIOLOGY (2021)
Highly accurate protein structure prediction with AlphaFold
John Jumper et al.
NATURE (2021)
Improved Antitumor Efficacy of Chimeric Antigen Receptor T Cells that Secrete Single-Domain Antibody Fragments
Yushu Joy Xie et al.
CANCER IMMUNOLOGY RESEARCH (2020)
Exploiting Single Domain Antibodies as Regulatory Parts to Modulate Monoterpenoid Production in E. coli
Jonathan Wilkes et al.
ACS SYNTHETIC BIOLOGY (2020)
Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer
Chaoyue Su et al.
FRONTIERS IN ONCOLOGY (2020)
PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer
Soyoung A. Oh et al.
NATURE CANCER (2020)
Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses
Daisuke Sugiura et al.
SCIENCE (2019)
Investigation of protein-protein interactions and hot spot region between PD-1 and PD-L1 by fragment molecular orbital method
Hocheol Lim et al.
SCIENTIFIC REPORTS (2019)
PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways
Yunlong Zhao et al.
IMMUNITY (2019)
Dimers Aren't Forever: CD80 Breaks up with PD-L1
David M. Sansom et al.
IMMUNITY (2019)
PD-L1 Binds to B7-1 Only In Cis on the Same Cell Surface
Apoorvi Chaudhri et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Multi-position data collection and dynamic beam sizing: recent improvements to the automatic data-collection algorithms on MASSIF-1
Olof Svensson et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2018)
Structural Basis of Epitope Recognition by Heavy-Chain Camelid Antibodies
Uros Zavrtanik et al.
JOURNAL OF MOLECULAR BIOLOGY (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy
Kefang Liu et al.
CELL RESEARCH (2017)
Structural evaluation of a nanobody targeting complement receptor Vsig4 and its cross reactivity
Yurong Wen et al.
IMMUNOBIOLOGY (2017)
PD-L1 is an activation-independent marker of brown adipocytes
Jessica R. Ingram et al.
NATURE COMMUNICATIONS (2017)
Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab
Fei Zhang et al.
ONCOTARGET (2017)
Antibody or Antibody Fragments: Implications for Molecular Imaging and Targeted Therapy of Solid Tumors
Katerina T. Xenaki et al.
FRONTIERS IN IMMUNOLOGY (2017)
Type VI secretion TssK baseplate protein exhibits structural similarity with phage receptor-binding proteins and evolved to bind themembrane complex
Van Son Nguyen et al.
NATURE MICROBIOLOGY (2017)
Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade
Fei Zhang et al.
CELL DISCOVERY (2017)
Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
Hyun Tae Lee et al.
SCIENTIFIC REPORTS (2017)
MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets
Sudhir Kumar et al.
MOLECULAR BIOLOGY AND EVOLUTION (2016)
DockQ: A Quality Measure for Protein-Protein Docking Models
Sankar Basu et al.
PLOS ONE (2016)
Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant
Roberta Pascolutti et al.
STRUCTURE (2016)
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
Sandip Pravin Patel et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1
Krzysztof M. Zak et al.
STRUCTURE (2015)
NMRFAM-SPARKY: enhanced software for biomolecular NMR spectroscopy
Woonghee Lee et al.
BIOINFORMATICS (2015)
15N, 13C and 1H resonance assignments and secondary structure determination of a variable heavy domain of a heavy chain antibody
Christine E. Prosser et al.
BIOMOLECULAR NMR ASSIGNMENTS (2014)
Deciphering key features in protein structures with the new ENDscript server
Xavier Robert et al.
NUCLEIC ACIDS RESEARCH (2014)
How good are my data and what is the resolution?
Philip R. Evans et al.
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY (2013)
Nanobodies: Natural Single-Domain Antibodies
Serge Muyldermans
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 82 (2013)
Structure and Interactions of the Human Programmed Cell Death 1 Receptor
Xiaoxiao Cheng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
REFMAC5 for the refinement of macromolecular crystal structures
Garib N. Murshudov et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2011)
Overview of the CCP4 suite and current developments
Martyn D. Winn et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2011)
Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega
Fabian Sievers et al.
MOLECULAR SYSTEMS BIOLOGY (2011)
Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4
Omar S. Qureshi et al.
SCIENCE (2011)
XDS
Wolfgang Kabsch
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY (2010)
The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors
David Yin-Wei Lin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
CTLA-4 control over Foxp3+ regulatory T cell function
Kajsa Wing et al.
SCIENCE (2008)
Inhibitory B7-family molecules in the tumour microenvironment
Weiping Zou et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Inference of macromolecular assemblies from crystalline state
Evgeny Krissinel et al.
JOURNAL OF MOLECULAR BIOLOGY (2007)
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses
Manish J. Butte et al.
IMMUNITY (2007)
Blockade of CTLA-4 on CD4+ CD25+ regulatory T cells abrogates their function in vivo
Simon Read et al.
JOURNAL OF IMMUNOLOGY (2006)
Likelihood-enhanced fast translation functions
AJ McCoy et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2005)
Crystal structure of a soluble CD28-Fab complex
EJ Evans et al.
NATURE IMMUNOLOGY (2005)
Structural and functional analysis of the costimulatory receptor programmed death-1
XW Zhang et al.
IMMUNITY (2004)
Coot:: model-building tools for molecular graphics
P Emsley et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2004)
SWISS-MODEL: an automated protein homology-modeling server
T Schwede et al.
NUCLEIC ACIDS RESEARCH (2003)
Expression of programmed death 1 ligands by murine T cells and APC
T Yamazaki et al.
JOURNAL OF IMMUNOLOGY (2002)
A p22 scaffold protein mutation increases the robustness of head assembly in the presence of excess portal protein
SD Moore et al.
JOURNAL OF VIROLOGY (2002)
The interaction properties of costimulatory molecules revisited
AV Collins et al.
IMMUNITY (2002)
Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses
CC Stamper et al.
NATURE (2001)
PD-L2 is a second ligand for PD-I and inhibits T cell activation
Y Latchman et al.
NATURE IMMUNOLOGY (2001)
Immunologic self-tolerance maintained by CD25+CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4
T Takahashi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Structure and dimerization of a soluble form of B7-1
S Ikemizu et al.
IMMUNITY (2000)
分享论文
